Airbnb, Inc. vs Boston Scientific Corporation — how do they compare? Airbnb, Inc. trades at $184.78 (market cap $110.76B), while Boston Scientific Corporation trades at $51.15 (market cap $74.19B). The key difference: Airbnb, Inc. is the larger of the two by market cap, and Airbnb, Inc. is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ABNB | BSX | |
|---|---|---|
Market Cap | $110.76B | $74.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $108.14 |
52-Week Low | $111.54 | $42.63 |
Enterprise Value | $101.19B | $86.27B |
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $184.70, up 3.72% in 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving averages and recent earnings beat in Q2 2026. Revenue growth is steady, with 2025 revenue at $12.24 billion and net income of $2.51 billion, though Q4 2025 and Q1 2026 EPS missed expectations. Analyst sentiment is mixed with a consensus price target of $173.26, below the current price, and news highlights AI-driven growth initiatives.
Outlook is cautiously optimistic with AI expansion boosting bookings and margins, but high valuation ratios like a P/E of 42.23 pose risks. Competition and economic sensitivity are key concerns. Institutional holdings and bullish technical trends support upside potential if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →